

Lorenzo Castagnoli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2500304/publications.pdf>

Version: 2024-02-01

19
papers

690
citations

567281

15
h-index

839539

18
g-index

19
all docs

19
docs citations

19
times ranked

1494
citing authors

#	ARTICLE	IF	CITATIONS
1	WNT signaling modulates PD-L1 expression in the stem cell compartment of triple-negative breast cancer. <i>Oncogene</i> , 2019, 38, 4047-4060.	5.9	137
2	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	7.0	76
3	The Human Splice Variant $\hat{1}$ 16HER2 Induces Rapid Tumor Onset in a Reporter Transgenic Mouse. <i>PLoS ONE</i> , 2011, 6, e18727.	2.5	70
4	Activated d16HER2 Homodimers and SRC Kinase Mediate Optimal Efficacy for Trastuzumab. <i>Cancer Research</i> , 2014, 74, 6248-6259.	0.9	63
5	HSPH1 inhibition downregulates Bcl-6 and c-Myc and hampers the growth of human aggressive B-cell non-Hodgkin lymphoma. <i>Blood</i> , 2015, 125, 1768-1771.	1.4	40
6	Pathobiological implications of the d16HER2 splice variant for stemness and aggressiveness of HER2-positive breast cancer. <i>Oncogene</i> , 2017, 36, 1721-1732.	5.9	36
7	Mutations in the external loops of BK virus VP1 and urine viral load in renal transplant recipients. <i>Journal of Cellular Physiology</i> , 2010, 222, 195-199.	4.1	34
8	Intratumor lactate levels reflect HER2 addiction status in HER2-positive breast cancer. <i>Journal of Cellular Physiology</i> , 2019, 234, 1768-1779.	4.1	31
9	Serological identification of HSP105 as a novel non-Hodgkin lymphoma therapeutic target. <i>Blood</i> , 2011, 118, 4421-4430.	1.4	30
10	c-MYC G-quadruplex binding by the RNA polymerase I inhibitor BMH-21 and analogues revealed by a combined NMR and biochemical Approach. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2018, 1862, 615-629.	2.4	29
11	HER2 Signaling and Breast Cancer Stem Cells: The Bridge behind HER2-Positive Breast Cancer Aggressiveness and Therapy Refractoriness. <i>Cancers</i> , 2021, 13, 4778.	3.7	27
12	Cancer Stem Cells: Devil or Savior? Looking behind the Scenes of Immunotherapy Failure. <i>Cells</i> , 2020, 9, 555.	4.1	26
13	The landscape of d16HER2 splice variant expression across HER2-positive cancers. <i>Scientific Reports</i> , 2019, 9, 3545.	3.3	22
14	The d16HER2 Splice Variant: A Friend or Foe of HER2-Positive Cancers?. <i>Cancers</i> , 2019, 11, 902.	3.7	21
15	Impact of systemic and tumor lipid metabolism on everolimus efficacy in advanced pancreatic neuroendocrine tumors (pNETs). <i>International Journal of Cancer</i> , 2019, 144, 1704-1712.	5.1	20
16	Inhibition of the Wnt Signalling Pathway: An Avenue to Control Breast Cancer Aggressiveness. <i>International Journal of Molecular Sciences</i> , 2020, 21, 9069.	4.1	16
17	Phenethyl isothiocyanate hampers growth and progression of HER2-positive breast and ovarian carcinoma by targeting their stem cell compartment. <i>Cellular Oncology (Dordrecht)</i> , 2019, 42, 815-828.	4.4	11
18	HSP105 Inhibition Counteracts Key Oncogenic Pathways and Hampers the Growth of Human Aggressive B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2012, 120, 1562-1562.	1.4	1

#	ARTICLE	IF	CITATIONS
19	Abstract 2314: d16HER2 splice variant regulates the activity of HER2-positive breast cancer-initiating cells. , 2015, , .		0